Public Companies
Irwin Naturals Acquires Kentucky Ketamine Clinic
Serenity is expected to add $3 million in EBITDA to Irwin’s financials.
The post Irwin Naturals Acquires Kentucky Ketamine Clinic appeared first on Green…
Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) continued its expansion spree with its acquisition of Serenity Health LLC, a ketamine clinic in Louisville, Kentucky.
Total consideration will be paid in upfront and deferred consideration. The deal also includes contingent payments based on milestones related to expansion and profitability goals.
The acquisition marks two key milestones in Irwin’s Emergence clinics growth strategy in the mental health industry. First, the acquisition is expected to be immediately accretive by adding an estimated $3 million in projected EBITDA, increasing the company’s annualized EBITDA by double digits. Second, the addition of this clinic further demonstrates Irwin’s ability to attract profitable clinics as part of its goal to establishing the world’s largest network of psychedelic mental health clinics.
The acquisition of Serenity Health brings the total number of clinics under the Irwin Naturals Emergence umbrella either under a definitive agreement, the Braxia letter of intent, or acquired to 22, including existing clinics in Florida, Vermont, New Hampshire, Iowa, and Georgia.
Irwin announced its intent to acquire Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) last month, though the price tag of that deal is yet to be determined. That move will expand Irwin’s operating footprint in both the U.S. and Canada.
The post Irwin Naturals Acquires Kentucky Ketamine Clinic appeared first on Green Market Report.
ketamine psychedelic cse otc deal braxia scientific braxia irwin naturals
-
Psilocybin1 week agoCalifornia advances bill for psychedelics centers
-
Psilocybin5 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoPsychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics5 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics6 days agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation5 days agoTryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics5 days agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics6 days agoOptimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research